GlobeNewswire: Zynerba Pharmaceuticals, Inc. Contains the last 10 of 227 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T11:40:41ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2023/10/04/2754937/0/en/Important-Information-for-Zynerba-Pharmaceuticals-Stockholders-to-Tender-Shares-for-the-Harmony-Transaction-Process-and-Instructions.html?f=22&fvtc=4&fvtv=26772Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions2023-10-04T20:05:00Z<![CDATA[DEVON, Pa., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today reminds all stockholders, including individual stockholders, to promptly tender their shares into the tender offer (the “Offer”) by Harmony Biosciences Holdings, Inc. (“Harmony”) and its wholly owned subsidiary, Xylophone Acquisition Corp. (“Purchaser”), to purchase all outstanding shares of Zynerba common stock. The Zynerba Board of Directors unanimously recommends that Zynerba stockholders tender their shares pursuant to the Offer.]]>https://www.globenewswire.com/news-release/2023/09/29/2752003/0/en/Zynerba-Pharmaceuticals-Stockholders-Reminded-to-Tender-Shares-Before-5-00-PM-New-York-City-Time-on-Tuesday-October-10-2023.html?f=22&fvtc=4&fvtv=26772Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023 2023-09-29T13:00:00Z<![CDATA[DEVON, Pa., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today released the following letter to stockholders concerning the pending tender offer by Harmony Biosciences Holdings, Inc. (“Harmony”).]]>https://www.globenewswire.com/news-release/2023/09/14/2743667/0/en/Zynerba-Pharmaceuticals-Presents-Positive-Data-from-Phase-2-INSPIRE-Trial-in-22q11-2-Deletion-Syndrome-at-The-Society-for-the-Study-of-Behavioural-Phenotypes-SSBP-25th-Internationa.html?f=22&fvtc=4&fvtv=26772Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium2023-09-14T20:15:00Z<![CDATA[Zygel™ (ZYN002) achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments and was generally well-tolerated through 38 weeks of treatment in INSPIRE, a Phase 2 trial with Zygel in children and adolescents with 22q11.2 deletion syndrome (22q) Zygel™ (ZYN002) achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments and was generally well-tolerated through 38 weeks of treatment in INSPIRE, a Phase 2 trial with Zygel in children and adolescents with 22q11.2 deletion syndrome (22q)]]>https://www.globenewswire.com/news-release/2023/08/08/2721138/0/en/Zynerba-Pharmaceuticals-Announces-New-Date-for-Reconvened-Annual-Meeting.html?f=22&fvtc=4&fvtv=26772Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting2023-08-08T20:05:00Z<![CDATA[Annual Meeting to Reconvene on August 25, 2023 at 9:00 a.m. EDT Annual Meeting to Reconvene on August 25, 2023 at 9:00 a.m. EDT]]>https://www.globenewswire.com/news-release/2023/07/25/2710936/0/en/Zynerba-Pharmaceuticals-Announces-New-Date-for-Reconvened-Annual-Meeting.html?f=22&fvtc=4&fvtv=26772Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting2023-07-25T21:18:44Z<![CDATA[Annual Meeting to Reconvene on August 11, 2023 at 9:00 a.m. EDT Annual Meeting to Reconvene on August 11, 2023 at 9:00 a.m. EDT]]>https://www.globenewswire.com/news-release/2023/06/28/2696601/0/en/Zynerba-Pharmaceuticals-Announces-Further-Adjournment-of-Annual-Meeting.html?f=22&fvtc=4&fvtv=26772Zynerba Pharmaceuticals Announces Further Adjournment of Annual Meeting2023-06-28T20:05:00Z<![CDATA[Annual Meeting Reconvened and Adjourned Without Conducting Business]]>https://www.globenewswire.com/news-release/2023/06/20/2690896/0/en/Zynerba-Pharmaceuticals-to-Present-at-the-H-C-Wainwright-4th-Annual-Neuropsychiatry-Virtual-Conference.html?f=22&fvtc=4&fvtv=26772Zynerba Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference2023-06-20T11:00:00Z<![CDATA[DEVON, Pa., June 20, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference being held June 26, 2023.]]>https://www.globenewswire.com/news-release/2023/06/13/2687646/0/en/Zynerba-Pharmaceuticals-Announces-Partial-Adjournment-of-Annual-Meeting.html?f=22&fvtc=4&fvtv=26772Zynerba Pharmaceuticals Announces Partial Adjournment of Annual Meeting2023-06-13T20:05:00Z<![CDATA[Meeting adjourned with respect to Proposal 2, Reverse Stock Split; Company encourages additional stockholders of record to vote before reconvened meeting on June 28, 2023]]>https://www.globenewswire.com/news-release/2023/05/23/2674139/0/en/Zynerba-Pharmaceuticals-Announces-Podium-and-Poster-Presentations-at-the-American-Society-of-Clinical-Psychopharmacology-Annual-Meeting.html?f=22&fvtc=4&fvtv=26772Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the American Society of Clinical Psychopharmacology Annual Meeting2023-05-23T11:00:00Z<![CDATA[DEVON, Pa., May 23, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced an oral podium presentation and poster presentations at the American Society of Clinical Psychopharmacology Annual Meeting (ASCP 2023), being held May 30 – June 2, 2023, in Miami, Fla. Copies of the presentations will be made available on the Zynerba corporate website following the presentations at http://zynerba.com/publications/.]]>https://www.globenewswire.com/news-release/2023/05/15/2668581/0/en/Zynerba-Pharmaceuticals-Reports-First-Quarter-2023-Financial-Results-and-Operational-Highlights.html?f=22&fvtc=4&fvtv=26772Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights2023-05-15T11:00:00Z<![CDATA[Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome; topline results expected first-half 2024]]>